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Abstract
Background: We recently reported on the enhanced tubular expression of two discrete isoforms of the MMP-2 (full
length and N-terminal truncated, FL-MMP-2, NTT-MMP-2) in a murine model and human diabetic kidneys. In the
present study, we examined in more detail the temporal and spatial distributions of MMP-2 isoform expression in
murine models of Type 1 and Type 2 diabetes mellitus.
Methods: Diabetic models were streptozotocin (STZ)-induced diabetes (Type 1 diabetes mellitus) and db/db mice
(Type 2 diabetes mellitus). We quantified the abundance of two isoforms of MMP-2 transcripts by qPCR. A spatial
distribution of two isoforms of MMP-2 was analyzed semi-quantitatively according to time after injection of STZ and
with increasing age of db/db mice. Furthermore, immunohistochemistry for nitrotyrosine was performed to
examine a potential association between oxidative stress and MMP-2 isoform expression.
Results: Both isoforms of MMP-2 were upregulated in whole kidneys from STZ and db/db mice. In the case of FL-
MMP-2, mRNA levels significantly increased at 12 and 24 weeks in STZ mice, while the isoform expression was
significantly increased only at 16 weeks, in the db/db mice. FL-MMP-2 protein levels increased in the cortices and
outer medullae of both STZ and db/db mice as a function of the duration of diabetes. For NTT-MMP-2, mRNA levels
increased earlier at 4 weeks in STZ mice and at 10 weeks of age in db/db mice. The expression of NTT-MMP-2 also
increased, primarily in the cortices of STZ and db/db mice, as a function of the duration of diabetes. Quantitatively,
these findings were consistent with the qPCR results in the case of NTT-MMP-2, respectively (STZ 24 weeks, 3.24 ± 3.
70 fold; 16 weeks db/db, 4.49 ± 0.55 fold). In addition, nitrotyrosine was expressed primarily in cortex as compared
to medulla as a function of the duration of diabetes similar to NTT-MMP-2 expression.
Conclusions: Two isoforms of MMP-2 are highly inducible in two diabetic murine models and become more
abundant as a function of time. As the expression patterns were not the same in the two isoforms of MMP-2, it is
possible that each isoform has a discrete role in the development of diabetic renal injury.
Keywords: Diabetes mellitus, Hyperglycemia, Matrix metalloproteinase-2, Oxidative stress
* Correspondence: shsong0209@gmail.com
This study was presented as a poster in 2017 ERA-EDTA 54th Congress.
†Il Young Kim and Sang Soo Kim contributed equally to this work.
1Biomedical Research Institute and Department of Internal Medicine, Pusan
National University Hospital, Gudeok-ro 179 Seo-gu, Busan 49241, Republic of
Korea
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Kim et al. BMC Nephrology  (2018) 19:248 
https://doi.org/10.1186/s12882-018-1029-8
Background
Diabetes mellitus (DM) is the most common
lifestyle-related disease and a heavy public health burden.
In addition, the prevalence of DM is increasing very rap-
idly worldwide [1]. More than 2.7 million Koreans aged
30 years or older have Type 2 DM and the prevalence of
an elevated fasting glucose was approximately 25.0% in
2013 [2]. Moreover, diabetes mellitus is the most common
etiology of end-stage renal disease (ESRD) and accounts
for 48.4% of new ESRD patients in 2015 Korean Registry
[3]. Diabetic nephropathy is the most representative renal
complication and related to injury to renal tubular cells
and various cells of glomeruli. Given the prevalence and
the extent of progression to ESRD, further elucidation of
core pathophysiologic mechanisms of diabetic nephropa-
thy is an important research goal.
Our laboratories have identified matrix
metalloproteinase-2 (MMP-2) as a central mediator of
acute and chronic renal injury in both experimental and
human clinical settings [4–7]. Transgenic renal tubular epi-
thelial cell expression of the full length, secreted isoform of
MMP-2 (FL-MMP-2) results in loss of tubular basement
membrane integrity, with resultant tubular atrophy, inter-
stitial fibrosis and inflammation [6]. More recently, we have
identified a novel intracellular isoform of MMP-2, called
N-terminal truncated isoform of MMP-2 (NTT-MMP-2)
[8]. The NTT-MMP-2 isoform lacks a secretory sequence
and the inhibitory propeptide and remains intracellular in
association with mitochondria in an enzymatically active
form [7, 8]. NTT-MMP-2 isoform activation contributed to
tubular epithelial cell regulated necrosis, which induced by
the mitochondrial permeability transition and enhancement
of sensitivity to ischemia/reperfusion injury [5]. Moreover,
we tried to explore the expression of two isoforms of
MMP-2 in diabetic kidney and firstly reported on the en-
hanced tubular epithelial cell expression of the FL-MMP-2
and NTT-MMP-2 isoforms in the murine streptozotocin
model of Type 1 diabetes mellitus and in archival renal
biopsies from patients with diabetic nephropathy [9]. So,
we hypothesized that two isoforms of MMP2 can be
important mediators in diabetic injury and the current
study was designed to expand on these initial observations
and to determine if differences exist between the spatial
and temporal patterns of MMP-2 isoform expression in
murine models of Type 1 (streptozotocin) and Type 2 (db/
db mice) diabetic nephropathy. The findings of this study
will provide a solid foundation for future studies to uncover
mechanisms related to diabetic renal injury.
Methods
Murine models of diabetic nephropathy
The animal protocol (2014–069, 2016–102) used in this
study was reviewed and approved by the Pusan National
University–Institutional Animal Care and Use Committee
(PNU-IACUC) regarding their ethical procedures and sci-
entific care. Mice were randomized into control and dia-
betic groups. The first diabetic murine model was induced
by five daily intraperitoneal injections of streptozotocin
(STZ, 40 mg/kg in citrate buffer, pH 4.5, Sigma-Aldrich)
in 8 week-old C57/BL6 male mice as described in the pre-
vious report [9]. This murine model is representative of
Type 1 diabetes mellitus. The control mice received citrate
buffer alone. STZ-induced diabetic mice were euthanized
under isoflurane anesthesia at 4, 8, 12 and 24 weeks after
the completion of STZ injection. Control mice were eu-
thanized by same method at 12 weeks after the comple-
tion of citrate buffer without STZ. Each group was
comprised of eight mice and was evaluated at 4, 8, 12 and
24 weeks following STZ treatment.
Male db/db mice (BKS.Cg-m+/+Leprdb/BomTac, Samta-
kobiokorea, South Korea) were used as a model of Type 2
diabetes mellitus. Control and db/m (heterozygote) male
mice were obtained at the same time from the same com-
pany. The three study groups were euthanized under iso-
flurane anesthesia at 10 and 16 weeks of age. All kidneys
were perfused with 4 °C phosphate-buffered saline (PBS)
and then excised. Half of the kidney was fixed in 10% neu-
tralized formalin for immunohistochemistry and the
remaining portions were used for quantitative polymerase
chain reaction (qPCR) analyses as detailed below. Table 1
summarized the characteristics of both diabetic mice model
including body weight, kidney weight and albuminuria.
Quantitative polymerase chain reaction (PCR) analysis
The FL-MMP-2 and NTT-MMP-2 mRNA expression
levels were measured by quantitative RT-PCR (qPCR). The
procedures were described in the previous report in detail
[9]. β-actin as the housekeeping internal control was quan-
tified in parallel with the target genes and all products were
verified by melting curve analysis (95 °C 15 s, 60 °C 15 s,
95 °C 15 s). Normalization and the fold-changes for each of
the genes were calculated using the 2-ΔΔCT method. The
primers used for qPCR are summarized in Table 2.
Microscopic analysis/immunohistochemistry
The tissues were fixed in 10% formalin immediately after
collection. Subsequently, the tissues were paraffin-processed
and embedded. The periodic acid-Schiff (PAS) stain and
Masson’s trichrome (MT) stain were performed to analyze
any diabetic tissue injury and fibrosis. In addition, immuno-
histochemistry was performed on formalin-fixed 3 μm thick
paraffin embedded sections. All of the procedures were
conducted in the same way as the previous paper [9]. An
isoform-specific antibody for NTT-MMP-2 targets the S1’
substrate binding loop as reported in detail [5] and antibody
to FL-MMP-2 was purchased from Abcam (ab3158, Abcam,
Cambridge, UK). Simultaneouly, immunostaining using
negative control omitting the primary antibody was
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conducted to ensure the specificity of the immunodetection.
The semi-quantitative staining grade was measured as fol-
lows: grade 0, negative staining; grade 1, weak patchy stain-
ing; grade 2, weak diffuse or dense patchy staining; and
grade 3, dense diffuse staining. For the assessement of oxida-
tive stress in the diabetic kidneys, immunostaining for the
marker of oxidative stress, nitrotyrosine was performed with
mouse monoclonal antibody [EM-30] to nitrotyrosine
(ab125106, Abcam, Cambridge, UK). We conducted correl-
ation analysis between NTT-MMP-2 transcript abundance
and nitrotyrosin IHC staining score. For two isoforms of
MMP-2 transcript abundance, we used the 2-ΔCT method of
analysis. Nitrotyrosin IHC scoring was performed as follows:
0, negative staining; 1, weak patch staining; 2, weak diffuse
staining or dense patch staining; 3, dense diffuse staining.
Statistical analysis
All statistical analyses were performed using GraphPad Prism
6.0 (GraphPad Software). The Kruskal-Wallis test with
Dunn’s multiple comparison test or Mann Whitney U test
were used to compare the experimental groups where appro-
priate. The spearman correlation analysis was conducted to
prove the correlation between nitrotyrosine score and tran-
scripts of both isoforms of MMP-2. A p-value of less than
0.05 was considered significant. The results are presented as
the median (interquartile range) for all experiments.
Results
Streptozotocin model of type 1diabetes mellitus
Quantitative PCR showed that the FL-MMP-2 and
NTT-MMP-2 transcripts were increased as compared to the
non-diabetic control mice as function of the duration of dia-
betes (Fig. 1-a, b). In the case of FL-MMP-2, transcript abun-
dance measured by quantitative PCR was significantly
increased by 18.2 (14.0–21.7) fold and 13.1 (1.6–17.7) fold at
12 weeks and 24 weeks, respectively (p < 0.01). In the case of
NTT-MMP-2, the transcripts were significantly increased 3.0
(2.3–4.9) fold at 4 weeks after the last STZ injection.
NTT-MMP-2 transcript abundance was increased 2.5 (1.5–
8.3) fold and 2.5 (2.1–5.5) fold at 12 and 24 weeks, respect-
ively, p= 0.017). These experiments indicate that expression
of the FL-MMP-2 and NTT-MMP-2 isoform transcripts
have distinct temporal patterns in the STZ model of Type 1
diabetes mellitus, with NTT-MMP-2 isoform expression oc-
curring significantly earlier than that of FL-MMP-2.
Figure 2 summarizes the results for IHC staining of renal
cross sections for the FL-MMP-2 and NTT-MMP-2 iso-
forms in the STZ model. As shown in Fig. 2, panel I, there is
low, but detectable expression of the FL-MMP-2 isoform in
the renal cortex of control kidneys. In parallel with the qPCR
studies of FL-MMP-2 transcript abundance, there no signifi-
cant increase in IHC staining at 4 and 8 weeks. Prominent
IHC staining for the FL-MMP-2 isoform was evident at 12
and 24 weeks in both the cortex and medulla. At both time
points, cortical staining was comparable with medullary
staining. Panel II, A and B, summarize semi-quantitative
scoring of IHC staining for the FL-MMP-2 isoform.
In contrast to the FL-MMP-2 isoform, NTT-MMP-2 was
not detectable by IHC in the either the cortex or medulla of
control kidneys. At 4 weeks following STZ injection,
NTT-MMP-2 signal was present primarily in the renal
cortex and the intensity increased at 8 weeks and was
Table 1 Charateristics of diabetic mice models
DM variables control (12wks) STZ 4wks STZ 8wks STZ 12wks STZ 24wks p-value
Type 1 BW (gm) Initial 23(23–23.8) 23.5(23–24) 23.5(22.8–24) 23(23–23) 23(23–24) 0.684
Last 31(29.2–32.8) 27(26.3–27.3) 26(25–28.5) 26(25–27.8) 29(27–32) 0.001
KW/BW (mg/mg) 0.005 (0.005–0.006) 0.008 (0.007–0.010) 0.008 (0.008–0.008) 0.008 (0.007–0.008) 0.009 (0.008–0.011) < 0.001
ACR (μg/mg) 48.0 (31.6–58.9) 90.6 (78.5–97.5) 70.3 (39.0–101.5) 0.002
DM variables control db/db db/db p-value
(db/m 10wks) (10wks) (16wks)
Type 2 BW Initial 24(24–26) 45(45–46) 45.5(43.5–47.5) 0.043
Last 25(25–28) 48(45–49) 55(50.5–58.8) 0.001
KW/BW (mg/mg) 0.006 (0.005–0.008) 0.004 (0.004–0.004) 0.004 (0.004–0.005) 0.045
ACR (μg/mg) 77.5 (75.9–84.2) 1000 (702.5–2274.0) 1333 (975.3–3755.0) 0.05
Abbreviations: DM diabetes mellitus; STZ streptozotocin; BW body weight; KW/BW kidney weight/body weight; ACR albumin creatinine ratio
Table 2 Quantitative polymerase chain reaction primer sequences
Genes Forward (5’➔3′) Reverse (5’➔3′)
Full length MMP-2 (mouse) GACCTCTGCGGGTTCTCTGC TTGCAACTCTCCTTGGGGCAGC
N-terminal truncated MMP-2 (mouse) GTGAATCACCCCACTGGTGGGTG TTGCAACTCTCCTTGGGGCAGC
β-actin (mouse control) CTCTCTTCCAGCCTTCCTTCC CTCCTTCTGCATCCTGTCAGC
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primarily limited to the cortex. Panel II, C and D summarize
semi-quantitative IHC scoring for the NTT-MMP-2 isoform.
Db/db model of type 2 diabetes mellitus
Quantitative PCR results for expression of the two MMP-2
isoforms in the kidney using the db/db model of Type 2
diabetes mellitus are summarized in Fig. 3. Expression of the
FL-MMP-2 transcript in kidneys was not significantly
increased until 10 weeks of age, and was only significantly
increased at 16 weeks of age by approximately three-fold as
compared to controls. In contrast, NTT-MMP-2 transcript
abundance was increased nearly 6-fold by 10 weeks of age.
Figure 4 summarizes the results for IHC staining for the
MMP-2 isoforms in the db/db model kidneys. The
FL-MMP-2 isoform was detected in both the cortex and me-
dulla at 10 and 16 weeks of age, in each case expression of
Fig. 1 Quantitative PCR measurement FL-MMP-2 (a) and NTT-MMP-2 (b) transcript levels in the STZ model of Type 1 diabetes mellitus. qPCR
performed on transcripts isolated from whole kidneys of controls and following 4, 8, 12, and 24 weeks after STZ injection. (N= 8 for each group; * p< 0.05)
Fig. 2 Immunohistochemical staining of kidneys for FL-MMP-2 and NTT-MMP-2 in the STZ model of Type 1 diabetes mellitus. MMP-2 isoform
specific IHC was performed as detailed in Methods. Panel I: IHC staining for FL-MMP-2 and NTT-MMP-2 for controls and at 4, 8, 12 and 24 weeks
following STZ treatment. There is low basal staining for the FL-MMP-2 isoform in the cortex of control kidneys, while NTT-MMP-2 is not detected.
IHC staining for both isoforms progressively increases as a function of time and staining is most prominent in the renal cortex. Panel II: Semi-quantitative
scoring of IHC staining. (N= 8 for each group; * p< 0.05; X10))
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the FL-MMP-2 in the cortex was comparable with the me-
dulla. Panel II, A and B summarize the semi-quantitative
IHC staining for the FL-MMP-2 isoform. The NTT-MMP-2
isoform was detected mainly in the renal cortex, but not
prominent in the medulla of db/db kidneys. Panel II, C and
D summarize the semi-quantitative IHC staining for the
NTT-MMP-2 isoform.
We performed PAS and Masson trichrome staining on the
kidneys from STZ-treated and db/db mice to determine if a
correlation exists between the timing of MMP-2 isoform ex-
pression and tubular injury and fibrosis. Representative
PAS-stained sections for the STZ-treated mice are shown in
Fig. 5, Panel I. Masson trichrome-stained sections are shown
in Fig. 5, Panel II. At four weeks following STZ treatment
the PAS and Masson trichrome sections are histologically
normal. At 8 weeks following STZ treatment, a time at
which NTT-MMP-2, but not FL-MMP-2 was upregulated
(Figs. 1, 2) there was evidence for cytoplasmic vacuolization
of the proximal tubule epithelial cells; however, there was no
evidence for fibrosis as determined by Masson trichrome
staining. By 24 weeks following STZ treatment when both
the FL-MMP-2 and NTT-MMP-2 isoforms are upregulated,
there was evidence for widespread proximal tubular epithe-
lial cell necrosis with tubular lumens filled with necrotic cells
Fig. 3 Quantitative PCR measurement of FL-MMP-2 (a) and NTT-MMP-2 (b) transcript levels in the db/db model of Type 2 diabetes mellitus. qPCR
performed on transcripts isolated from while kidneys of db/m controls and from db/db mice at 10 and 16 weeks of age. (N = 8 for each group; * p< 0.05)
Fig. 4 Immunohistochemical staining of kidneys from FL-MMP-2 and NTT-MMP-2 in the db/db model of Type 2 diabetes mellitus. Panel I. There
is a low basal expression of FL-MMP-2 and NTT-MMP-2 in the cortex of control db/m kidneys. Staining for both isoforms increases in the db/db
kidneys at 10 and 16 weeks. Panel lI. Semi-quantitative scoring of IHC staining. (N = 8 for each group; * p < 0.05; X10)
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in PAS-stained renal sections. In contrast to the widespread
tubular epithelial cell necrosis at 24 weeks, there were only
rare small foci of fibrosis.
We performed similar analyses with PAS and Masson tri-
chrome staining on the db/db mice at 10 and 16 weeks of
age. Representative results of these studies are shown in Fig. 6,
Panels I and II. Proximal tubular epithelial cell vacuolization
was present in the 10 week old db/db kidneys and by 16 weeks
there was evidence for tubular epithelial cell necrosis with
tubular dilation. Masson trichrome staining revealed only oc-
casional patchy foci of fibrosis in the 16 week old db/db mice,
which were not present in the 10 week old db/db mice.
We have recently reported that transgenic expression of
the NTT-MMP-2 isoform in renal proximal tubular epithelial
cells induces oxidative stress mediated by initiation of the
mitochondrial permeability transition [5]. We used IHC stain-
ing for nitrotyrosine as a marker of oxidative stress and repre-
sentative results of these studies are presented in Fig. 7. As
compared to controls, there was no increase in nitrotyrosine
IHC staining at 4 weeks following STZ treatment; however,
there was prominent staining for nitrotyrosine at 12 weeks
following STZ treatment. Notably, nitrotyrosine staining was
considerably stronger in the cortex as opposed to the me-
dulla. Nitrotyrosine staining was not detectable in the kidneys
of 10 weeks old db/m kidneys, but was readily detected in
kidneys of 16 week old db/db mice (Fig. 7-I, II). As with the
STZ-treated mice, nitrotyrosine staining was much more
abundant in the cortex as compared to the medulla. The tem-
poral patterns and expression levels of nitrotyrosine expres-
sion, a marker of oxidative stress, correlated with qPCR
determination of MMP-2 isoform expression (Fig. 7-III).
Discussion
The principal findings of this study are that two discrete
MMP-2 isoforms are induced in kidneys of murine models
representative of Type 1 and Type 2 diabetes. In particular,
the expression patterns of FL-MMP-2 and NTT-MMP-2
differed according to the anatomical location and the length
of time with hyperglycemia. In the context of the time of a
diabetic milieu, NTT-MMP-2 was more significantly
Fig. 5 PAS and Masson trichrome staining of kidneys from the STZ model of Type 1 diabetes mellitus. Panel I: PAS staining of renal cortex at 4, 8
and 24 weeks after STZ treatment. PAS staining is normal in the 4 week STZ group, while vacuolization of tubular epithelial cells is present at
8 weeks (arrow). By 24 weeks there is widespread tubular epithelial cell necrosis with cellular debris in the tubular lumens (arrows). Panel II:
Masson trichrome staining of kidneys at 4, 8 and 24 weeks following STZ treatment. There is no detectable fibrosis at 4 and 8 weeks, while there
are small foci of fibrosis (blue staining) in the cortex of kidneys at 24 weeks (inset X400)
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induced earlier in both murine diabetic models as com-
pared to FL-MMP-2. In the context of the anatomical loca-
tion, although the two isoforms of MMP-2 were expressed
gradually in the renal cortical tubular segment according to
the time of the two different diabetic milieu, the expression
FL-MMP-2 in the outer medulla was more prominent as
compared to NTT-MMP-2. Interestingly, NTT-MMP-2
was not expressed in whole kidney of normoglycemic con-
trol mice, while low cortical levels of FL-MMP-2 were de-
tected by IHC in normoglycemic kidneys. In addition,
although IHC staining for NTT-MMP-2 revealed low, de-
tectable levels in the cortex of the db/m mice, the degree
was faint and its expression was not evident in the outer
medulla of db/m mice. In the later stage of the STZ in-
duced diabetic model, NTT-MMP-2 was upregulated
strongly in the cortex compared to the medulla. In the db/
db mice, the two isoforms of MMP-2 were more signifi-
cantly upregulated in cortex as compared with medulla.
Based on these findings and previous data, the abundance
of FL-MMP-2 and NTT-MMP-2 in the two diabetic ne-
phropathy models may be dependent on the degree of
hyperglycemia and the degree of associated oxidative stress.
Importantly, we showed that the upregulation of
NTT-MMP-2 preceded evidence for the tubular injury pat-
tern as previously reported in our transgenic model ex-
pressing NTT-MMP-2 in the renal proximal tubule [6].
To date, studies have provided conflcting data about the
roles of matrix metalloproteinases in both experimental and
clinical diabetic nephropathy [10]. MMP-2 can be expressed
in the whole segments anatomically in the animal kidney,
even though those kidneys were obtained from the rabbit,
rats, and monkeys [11]. The present study is valuable because
it defines the anatomical location (cortex vs. medulla) and
the time of induction of MMP-2 isoform induction by hyper-
glycemia in both type 1 and type 2 murine diabetic models.
The NTT-MMP-2 isoform was initially characterized
in isolated mitochondria from a murine model of sys-
tolic heart failure and accelerated atherogenesis and was
Fig. 6 PAS and Masson trichrome staining of kidneys from the db/db model of Type 2 diabetes mellitus. Panel I: PAS staining of control db/m
kidneys is normal. At 10 weeks of age kidneys of db/db mice show occasional tubular epithelial cell vacuolization (arrow), which is much more
extensive at 16 weeks of age (arrows). Panel II. Masson trichrome staining of control db/db kidneys at 10 and 16 weeks of age. There are rare,
scattered foci of fibrosis (blue) in the deep cortex at 16 weeks, but not at 10 weeks of age (inset X400)
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also detected in the cardiac mitochondrial fraction of
aged mice [8]. Subsequently, the NTT-MMP-2 isoform
expression significantly correlated with tubular epithelial
cell necrosis in human renal transplant delayed graft
function [7]. Hyperglycemia- induced oxidative stress is
considered as a major driver in diabetic nephropathy
[12–14]. We have demonstrated that oxidative stress
induces NTT-MMP-2 synthesis via activation of an al-
ternate promoter located in the first intron of the
MMP-2 gene [8]. Further, NTT-MMP-2, per se, induces
further oxidative stress via induction of the mitochon-
drial permeability transition, with resultant tubular epi-
thelial cell regulated necrosis [5]. The present study
shows that the nitrotyrosine expression in the kidney is
Fig. 7 Nitrotyrosine IHC of kidneys from STZ-treated and db/db mice. Panel I: Nitrotyrosine IHC from control kidneys (a, d) and at 4 weeks (b,
e)and 12 weeks (c, e) following STZ treatment. IHC staining for nitrotyrosine is absent in the controls but is detectable at 4 weeks and further
increased at 12 weeks. Nitrotyrosine IHC staining is most prominent within the cortex as compared to the medulla. (a-c X10; D-F X100). Panel II:
Nitrotyrosine IHC of kidneys from control db/m (a, c) and with 16 week old db/db kidneys (b, d). Nitrotyrosine IHC staining is concentrated in the
cortex of the 16 week old db/db kidneys and is not detected in the age-matched db/m controls. (a, b X 10; C,D X100). Panel III: Nitrotyrosin IHC
score is correlated with two isoforms of MMP-2 in STZ and control kidneys. In db/m and db/db kidneys, NTT-MMP-2 is only correlated with
nitrotyrosine ICH score. (R, correlation coefficient; CI, 95% confidence interval; ICH, immunohistochemistry)
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associated with the two isoforms of MMP-2, especially
NTT-MMP-2. In addition, the hyperglycemia and mito-
chondrial pathway of regulated necrosis can be related
to the increased susceptibility of rodent models and hu-
man with diabetes to ischemia-reperfusion injury [15].
Conclusions
Two isoforms of MMP-2 are consistently highly inducible in
murine models representative of type 1 and type 2 diabetes
and gradually become abundant over time of the diabetic mi-
lieu. As the expression patterns were not the same in the
two isoforms of MMP-2, it is possible that these isoforms
have a respective role in diabetic renal injury.
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